Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes

Gynecologic Oncology

Volumn 95, Issue 3, 2004, Pages 488-495

  Meng, Yuru ^a   Graves, Laura ^a   Do, Thuy Vy ^a   So, John ^a   Fishman, David A ^a  

^a NY 10016 ^*

Author keywords

Apoptosis; Epithelial ovarian cancer cells (EOC); FasL; LPA; T lymphocytes

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; FAS LIGAND; GELATINASE A; GELATINASE INHIBITOR; ILOMASTAT; LYSOPHOSPHATIDIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL SURFACE; COCULTURE; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFECT; EXOCYTOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; NORMAL HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SECRETORY VESICLE; SIGNAL TRANSDUCTION; STAINING; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 9944249687     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.07.052     Document Type: Article

References (39)

1. G.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber Cancer immunoediting: from immunosurveillance to tumor escape Nat. Immunol. 3 11 2002 991 998
2. S. Strand, W.J. Hofmann, H. Hug, M. Muller, G. Otto, and D. Strand Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-A mechanism of immune evasion? Nat. Med. 2 12 1996 1361 1366
3. S. Nagata Fas ligand-induced apoptosis Annu. Rev. Genet. 33 1999 29 55
4. H. Das, T. Koizumi, T. Sugimoto, S. Chakraborty, T. Ichimura, and K. Hasegawa Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RTPCR Br. J. Cancer 82 10 2000 1682 1688
5. H. Rabinowich, T.E. Reichert, Y. Kashii, B.R. Gastman, M.C. Bell, and T.L. Whiteside Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes J. Clin. Invest. 101 11 1998 2579 2588
6. C. van Haaften-Day, P. Russell, S. Davies, N.J. King, and M.H. Tattersall Expression of Fas and FasL in human serous ovarian epithelial tumors Hum. Pathol. 34 1 2003 74 79
7. H.O. Lee, and T.A. Ferguson Biology of FasL Cytokine Growth Factor Rev. 14 3-4 2003 325 335
8. H.R. Salih, G.C. Starling, M. Knauff, M.B. Llewellyn, P.M. Davis, and W.J. Pitts Retinoic acid and vitamin E modulate expression and release of CD178 in carcinoma cells: consequences for induction of apoptosis in CD95-sensitive cells Exp. Cell Res. 270 2 2001 248 258
9. D.A. Fishman, and K. Bozorgi The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP) Cancer Treat. Res. 107 2002 3 28
10. L.A. Liotta, E.F. Petricoin III, A.M. Ardekani, B.A. Hitt, P.J. Levine, V.A. Fusaro, S.M. Steinberg, G.B. Mills, C. Simone, D.A. Fishman, and E.C. Kohn General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer Gynecol. Oncol. 88 1 Pt. 2 2003 S25 S28 (discussion S37-42)
11. G.B. Mills, A. Eder, X. Fang, Y. Hasegawa, M. Mao, and Y. Lu Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer Cancer Treat. Res. 107 2002 259 283
12. X. Fang, D. Gaudette, T. Furui, M. Mao, V. Estrella, and A. Eder Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer Ann. N.Y. Acad. Sci. 905 2000 188 208
13. E.J. Goetzl, and S. An Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate FASEB J. 12 15 1998 1589 1598
14. D.A. Fishman, Y. Liu, S.M. Ellerbroek, and M.S. Stack Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells Cancer Res. 61 7 2001 3194 3199
15. R.L. Baldwin, H. Tran, and B.Y. Karlan Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis Gynecol. Oncol. 74 2 1999 265 271
16. S. Munakata, T. Enomoto, M. Tsujimoto, Y. Otsuki, and H. Miwa Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms Br. J. Cancer 82 8 2000 1446 1452
17. R.J. Davis MAPKs: new JNK expands the group Trends Biochem. Sci. 19 11 1994 470 473
18. E. Cano, and L.C. Mahadevan Parallel signal processing among mammalian MAPKs Trends Biochem. Sci. 20 3 1995 117 122
19. B. Su, and M. Karin Mitogen-activated protein kinase cascades and regulation of gene expression Curr. Opin. Immunol. 8 3 1996 402 411
20. R. Seger, and E.G. Krebs The MAPK signaling cascade FASEB J. 9 9 1995 726 735
21. J. Han, J.D. Lee, Y. Jiang, Z. Li, L. Feng, and R.J. Ulevitch Characterization of the structure and function of a novel MAP kinase kinase (MKK6) J. Biol. Chem. 271 6 1996 2886 2891
22. R.J. Mayer, and L.A. Marshall New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -nonselective enzymes FASEB J. 7 2 1993 339 348
23. A.M. Eder, T. Sasagawa, M. Mao, J. Aoki, and G.B. Mills Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2 Clin. Cancer Res. 6 6 2000 2482 2491
24. J. Takasaki, Y. Kawauchi, T. Yasunaga, and Y. Masuho Human type II phospholipase A2-induced Mac-1 expression on human neutrophils J. Leukoc. Biol. 60 2 1996 174 180
25. J. Takasaki, Y. Kawauchi, and Y. Masuho Synergistic effect of type II phospholipase A2 and platelet-activating factor on Mac-1 surface expression and exocytosis of gelatinase granules in human neutrophils: evidence for the 5-lipoxygenasedependent mechanism J. Immunol. 160 10 1998 5066 5072
26. M. Hernandez, L. Fuentes, F.J. Fernandez Aviles, M.S. Crespo, and M.L. Nieto Secretory phospholipase A(2) elicits proinflammatory changes and upregulates the surface expression of fas ligand in monocytic cells: potential relevance for atherogenesis Circ. Res. 90 1 2002 38 45
27. A. Huwiler, G. Staudt, R.M. Kramer, and J. Pfeilschifter Cross-talk between secretory phospholipase A2 and cytosolic phospholipase A2 in rat renal mesangial cells Biochim. Biophys. Acta 1348 3 1997 257 272
28. W.K. Han, A. Sapirstein, C.C. Hung, A. Alessandrini, and J.V. Bonventre Cross-talk between cytosolic phospholipase A2 alpha (cPLA2 alpha) and secretory phospholipase A2 (sPLA2) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells: sPLA2 regulates cPLA2 alpha activity that is responsible for arachidonic acid release J. Biol. Chem. 278 26 2003 24153 24163
29. T. Suda, H. Hashimoto, M. Tanaka, T. Ochi, and S. Nagata Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing J. Exp. Med. 186 12 1997 2045 2050
30. S.D. Webb, J.A. Sherratt, and R.G. Fish Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology Math. Biosci. 179 2 2002 113 129
31. T. Nozoe, M. Yasuda, M. Honda, S. Inutsuka, and D. Korenaga Fas ligand expression is correlated with metastasis in colorectal carcinoma Oncology 65 1 2003 83 88
32. H. Kase, Y. Aoki, and K. Tanaka Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression Gynecol. Oncol. 90 1 2003 70 74
33. J. Beltman, J.R. Erickson, G.A. Martin, J.F. Lyons, and S.J. Cook C3 toxin activates the stress signaling pathways, JNK and p38, but antagonizes the activation of AP-1 in rat-1 cells J. Biol. Chem. 274 6 1999 3772 3780
34. G. Bossi, and G.M. Griffiths Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells Nat. Med. 5 1 1999 90 96
35. E.J. Blott, G. Bossi, R. Clark, M. Zvelebil, and G.M. Griffiths Fas ligand is targeted to secretory lysosomes via a proline-rich domain in its cytoplasmic tail J. Cell Sci. 114 Pt. 13 2001 2405 2416
36. V.M. Abrahams, S.L. Straszewski, M. Kamsteeg, B. Hanczaruk, P.E. Schwartz, and T.J. Rutherford Epithelial ovarian cancer cells secrete functional Fas ligand Cancer Res. 63 17 2003 5573 5581
37. J. O'Connell, A. Houston, M.W. Bennett, G.C. O'Sullivan, and F. Shanahan Immune privilege or inflammation? Insights into the Fas ligand enigma Nat. Med. 7 3 2001 271 274
38. J.H. Li, D. Rosen, P. Sondel, and G. Berke Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells Immunology 105 3 2002 267 277
39. J. O'Connell Fas ligand and the fate of antitumour cytotoxic T lymphocytes Immunology 105 3 2002 263 266